# US 2021/0275532 A1 · Pyridopyrimidinone derivatives for use as axl inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275532 A1
- Document ID: US20210275532A1
- Status: Published application
- Kind: A1
- Application number: 17/255,589
- Filed: 2019-06-26
- Published: 2021-09-09
- Earliest claimed: 2018-06-27
- Assignees: Oscote Inc.
- Applicants: Oscotec Inc.
- Inventors: Jung-Ho KIM; Jang-Sik CHOI; Hee Kyu LEE; Dong-Sik JUNG; Sung-Ho PARK; Yung-Geun CHOI
- Web page: https://patentgrep.com/patent/US20210275532A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07D 471/04: Ortho-condensed systems
- A61K 2039/505: {comprising antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Pyridopyrimidinone derivatives and pharmaceutical compositions containing the same for use as an Axl inhibitor for the treatment of a disease or condition mediated by Axl such as cancer and metastasis, are disclosed. Also disclosed are methods for treating a Axl-mediated disease or condition by administering to a subject a therapeutically effective amount of the pyridopyrimidinone derivative.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method of inhibiting Axl in a subject in need thereof, comprising administering an effective amount of a composition comprising a compound of the following Formula (I) or a pharmaceutically acceptable salt thereof:
wherein
R1 is C6-C10aryl, C6-C10arylC1-C6alkyl, C5-C6cycloalkyl or C5-C6cycloalkylmethyl, optionally substituted with one or two R3s;
R3 is independently fluoro, chloro, bromo, iodo, C1-C6alkyl, or trifluoromethyl;
X is H, fluoro, chloro, bromo, iodo, methyl, or trifluoroethyl;
Y is chloro, bromo, iodo, C1-C3alkyl, or phenyl;
R2 is C3-C6cycloalkyl or 4 to 7-membered heterocycloalkyl, wherein the C3-C6cycloalkyl is optionally substituted at carbon atoms with one or two R4s, and wherein the 4 to 7-membered heterocycloalkyl has 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen, sulfur, sulfone and sulfoxide, and is optionally substituted at carbon atom with R4 or at nitrogen atom with R5;
R4 is independently hydroxy, hydroxyC1-C6alkyl, amino, aminoC1-C6alkyl, —NH(—C1-C3alkyl), —N(—C1-C3alkyl)2, C1-C3alkyl or halo; and
R5 is H, C1-C3alkyl or —C(═O)(—C1-C3alkyl), wherein the C1-C3alkyl is optionally substituted with 1 to 3 fluoros,
wherein the subject suffers from a disease or condition mediated by Axl.

### Claim 17 (depends on 16)

The method of claim 16, wherein R1 is phenyl, benzyl, cyclopentyl, cyclohexyl, cyclopentylmethyl, or cyclohexylmethyl, optionally substituted with one or two R3s; and R3 is independently fluoro, chloro, bromo, iodo, C1-C6alkyl, or trifluoromethyl.

### Claim 18 (depends on 16)

The method of claim 16, wherein R2 is piperidinyl or pyrrolidinyl substituted at nitrogen atom with R5; and R5 is H, C1-C3alkyl or —C(═O)(—C1-C3alkyl).

### Claim 19 (depends on 16)

The method of claim 16, where R5 is methyl, ethyl, trifluoroethyl, or i-propyl.

### Claim 20 (depends on 16)

The method of claim 16, wherein R3 is independently chloro or fluoro.

### Claim 21 (depends on 16)

The method of claim 16, wherein Y is bromo.

### Claim 22 (depends on 16)

The method of claim 16, wherein X is fluoro or methyl.

### Claim 23 (depends on 16)

The method of claim 16, wherein the compound of Formula (I) or a pharmaceutically acceptable salt thereof is 8-bromo-2-((1-methylpiperidin-4-yl)amino)-4-((4-phenoxyphenyl)amino)pyrido[4,3-d]pyrimidin-5 (6H)-one hydrochloride.

### Claim 24 (depends on 16)

The method of claim 16, wherein the compound of Formula (I) or a pharmaceutically acceptable salt thereof is 8-bromo-4-((4-(cyclopentyloxy)phenyl)amino)-2-((1-methylpiperidin-4-yl)amino)pyrido[4,3-d]pyrimidin-5 (6H)-one hydrochloride; or 8-bromo-4-((4-(3-fluorophenoxy)phenyl)amino)-2-((1-methylpiperidin-4-yl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one hydrochloride.

### Claim 25 (depends on 16)

The method of claim 16, wherein the compound of Formula (I) comprises a stereoisomer thereof.

### Claim 26 (depends on 16)

The method of claim 16, wherein the disease or condition is cancer mediated by Axl.

### Claim 27 (depends on 16)

The method of claim 16, wherein the disease or condition is acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, aids-related cancers, aids-related lymphoma, anal cancer, appendix cancer, astrocytomas, atypical teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, osteosarcoma and malignant fibrous histiocytoma, brain stem glioma, brain tumor, central nervous system atypical teratoid/rhabdoid tumor, astrocytomas, craniopharyngioma, ependymoblastoma, ependymoma, medulloblastoma, medulloepithelioma, pineal parenchymal tumors of intermediate differentiation, supratentorial primitive neuroectodermal tumors and pineoblastoma, brain and spinal cord tumors, breast cancer, bronchial tumors, burkitt lymphoma, carcinoid tumor, gastrointestinal cancer, central nervous system lymphoma, cervical cancer, chordoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colon cancer, colorectal cancer, craniopharyngioma, cutaneous t-cell lymphoma, mycosis fungoides, sezary syndrome, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, esthesioneuroblastoma, ewing sarcoma family of tumors, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, intraocular melanoma, retinoblastoma, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, gastrointestinal stromal cell tumor, extracranial germ cell tumor, extragonadal germ cell tumor, ovarian germ cell tumor, gestational trophoblastic tumor, glioma, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular cancer, histiocytosis, hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors, kaposi sarcoma, renal cell cancer, kidney cancer, langerhans cell histiocytosis, laryngeal cancer, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, leukemia, lip and oral cavity cancer, liver cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, aids-related lymphoma, burkitt lymphoma, cutaneous t-cell lymphoma, Hodgkin lymphoma, non-hodgkin lymphoma, primary central nervous system lymphoma, macroglobulinemia, malignant fibrous histiocytoma of bone and osteosarcoma, medulloblastoma, medulloepithelioma, melanoma, intraocular melanoma, merkel cell carcinoma, mesothelioma, metastatic squamous neck cancer with occult primary, mouth cancer, multiple endocrine neoplasia syndromes, multiple myeloma, plasma cell neoplasm, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, myelogenous leukemia, myeloid leukemia, myeloproliferative disorders, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-hodgkin lymphoma, non-small cell lung cancer, oral cancer, oral cavity cancer, oropharyngeal cancer, osteosarcoma and malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, papillomatosis, parathyroid cancer, penile cancer, pharyngeal cancer, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, pleuropulmonary blastoma, pregnancy and breast cancer, prostate cancer, rectal cancer, renal cell cancer, transitional cell cancer, respiratory tract cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, ewing sarcoma, kaposi sarcoma, uterine sarcoma, nonmelanoma skin cancer, melanoma skin cancer, skin carcinoma, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, squamous neck cancer, stomach cancer, supratentorial primitive neuroectodermal tumors, t-cell lymphoma, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, transitional cell cancer of the renal pelvis and ureter, trophoblastic tumor, gestational cancer, ureter and renal pelvis cancer, transitional cell cancer, urethral cancer, uterine cancer, endometrial cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom macroglobulinemia, or Wilms tumor.

### Claim 28 (depends on 16)

The method of claim 16, wherein the composition further comprises a pharmaceutically acceptable carrier, diluent, adjuvant, or excipient.

### Claim 29 (depends on 16)

The method of claim 16, wherein the composition comprising a compound of Formula (I) as an active ingredient, for the treatment of a disease or condition mediated by Axl.

### Claim 30 (depends on 16)

The method of claim 16, which further comprises administering an immune checkpoint blocker.

### Claim 31 (depends on 30)

The method of claim 30, wherein the immune checkpoint blocker is an anti-PD-1 antibody, anti-PDL antibody, or anti-CLTA4 antibody.

### Claim 32 (depends on 16)

The method of claim 16, wherein the subject has been or is undergone with a chemotherapy and/or irradiation.
